Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antimiR-210 SG608
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
**antimiR-210 SG608** is a chemically modified antisense oligonucleotide (antimiR) designed to inhibit microRNA-210 (miR-210). It features 2′-O-methyl modifications on all residues and ZEN moieties (N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine) at both the 5′- and 3′-ends for enhanced stability and potency. Developed for topical delivery via layer-by-layer (LbL) formulated mesh dressings, it accelerates wound healing in diabetic models by reducing miR-210 levels, which derepresses reporter gene expression up to threefold in luciferase biosensor assays (pSG247). In neuroischemic rabbit models of diabetic wounds, SG608 treatment significantly improved healing rates (p=0.038), reducing unclosed wound area to 5% vs. 18% in controls by day 20, with >99% miR-210 knockdown in tissues and no significant histological adverse effects.[1]
- Other names
- antimiR-210antimiR210antimiR 210
Beyond the preview
Go deeper on antimiR-210 SG608.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antimiR-210 SG608.